Buprenorphine is an opioid used to treat opioid use disorder, acute pain, and chronic pain.[8] It can be used under the tongue (sublingual), in the cheek (buccal), by injection (intravenous and subcutaneous), as a skin patch (transdermal), or as an implant.[8][9] For opioid use disorder, it is typically started when withdrawal symptoms have begun and for the first two days of treatment under direct observation of a health-care provider.[8] In the United States, the combination formulation of buprenorphine/naloxone (Suboxone) is usually prescribed to discourage misuse by injection.[8] Maximum pain relief is generally within an hour with effects up to 24 hours.[8] Buprenorphine affects different types of opioid receptors in different ways.[8] Depending on the type of receptor, it may be an agonist, partial agonist, or antagonist.[8] In the treatment of opioid use disorder buprenorphine is an agonist/antagonist, meaning that it relieves withdrawal symptoms from other opioids and induces some euphoria, but also blocks the ability for many other opioids, including heroin, to cause an effect. Unlike full agonists like heroin or methadone, buprenorphine has a ceiling effect, such that taking more medicine will not increase the effects of the drug.[10]

Clinical data
Trade namesSubutex, Sublocade, others
License data
Psychological: High; Physical: Moderate[2]
Routes of
Under the tongue, through the cheek, intramuscular, intravenous, transdermal, intranasal, rectally, by mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilitySublingual: 30%[4]
Intranasal: 48%[5]
Buccal: 65%[6][7]
Protein binding96%
MetabolismLiver (CYP3A4, CYP2C8)
Onset of actionWithin 30 min[8]
Elimination half-life37 hours (range 20–70 hours)
Duration of actionUp to 24 hrs[8]
ExcretionBile duct and kidney
  • (2S)-2-[(5R,6R,7R,14S)-17-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.052.664
Chemical and physical data
Molar mass467.650 g·mol−1
3D model (JSmol)
  • Oc7ccc5c1c7O[C@H]3[C@]6(OC)[C@H](C[C@@]2([C@H](N(CC[C@@]123)CC4CC4)C5)CC6)[C@@](O)(C)C(C)(C)C
  • InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1 Y
 NY (what is this?)  (verify)

Side effects may include respiratory depression (decreased breathing), sleepiness, adrenal insufficiency, QT prolongation, low blood pressure, allergic reactions, constipation, and opioid addiction.[8][11] Among those with a history of seizures, a risk exists of further seizures.[8] Opioid withdrawal following stopping buprenorphine is generally less severe than with other opioids.[8] Whether use during pregnancy is safe is unclear, but use while breastfeeding is probably safe, since the dose the infant receives is 1-2% that of the maternal dose, on a weight basis.[12][8]

Buprenorphine was patented in 1965, and approved for medical use in the United States in 1981.[8][13] It is on the World Health Organization's List of Essential Medicines.[14] In addition to prescription as an analgesic it is a common medication used to treat opioid use disorders, such as addiction to heroin.[15] In 2020, it was the 186th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[16][17] Buprenorphine may also be used recreationally for the high it produces, and in the US sublingual formulations are marketed as a film or mixed with naloxone to discourage injection.[15] In the United States, buprenorphine is a schedule III controlled substance.[15]

Medical uses

Opioid use disorder

Buprenorphine patches in the pouch with packaging: A removed patch is shown on the left. In Britain, buprenorphine patches are named Butec 5, Butec 10, and so on.

Buprenorphine is used to treat people with opioid use disorder.[8][18]:84–7 In the U.S., the combination formulation of buprenorphine/naloxone is generally prescribed to deter injection, since naloxone, an opioid antagonist, causes acute withdrawal if the formulation is crushed and injected.[8][19]:99 However, taken orally, the nalaxone has virtually no effect, due to the drug's extremely high first-pass metabolism and low bioavailability (2%).[20] Before starting buprenorphine, individuals are generally advised to wait long enough after their last dose of opioid until they have some withdrawal symptoms to allow for the medication to bind the receptors, since if taken too soon, buprenorphine can displace other opioids bound to the receptors and precipitate an acute withdrawal. The dose of buprenorphine is then adjusted until symptoms improve, and individuals remain on a maintenance dose of 8–16 mg.[19]:99–100[21] Because withdrawal is uncomfortable and a deterrent for many patients, many have begun to call for different means of treatment initiation.[22] Some providers have begun to use the Bernese method, also known as microdosing, in which very small doses of buprenorphine are given while patients are still using street opioids, and without precipitating withdrawal, with medicine levels slowly titrated upward.[23][24]

Buprenorphine versus methadone

Both buprenorphine and methadone are medications used for detoxification and opioid replacement therapy, and appear to have similar effectiveness based on limited data.[25] Both are safe for pregnant women with opioid use disorder,[19]:101[21] although preliminary evidence suggests that methadone is more likely to cause neonatal abstinence syndrome.[26] In the US and European Union, only designated clinics can prescribe methadone for opioid use disorder, requiring patients to travel to the clinic daily. If patients are drug free for a period they may be permitted to receive "take home doses," reducing their visits to as little as once a week. Alternatively, up to a month's supply of buprenorphine has been able to be prescribed by clinicians in the US or Europe who have completed a basic training (8–24 hours in the US) and received a waiver/licence allowing prescription of the medicine.[18]:84–5 In France, buprenorphine prescription for opioid use disorder has been permitted without any special training or restrictions since 1995, resulting in treatment of approximately ten times more patients per year with buprenorphine than with methadone in the following decade.[27] In 2021, seeking to address record levels of opioid overdose, the United States also removed the requirement for a special waiver for prescribing physicians.[28] Whether this change will be sufficient to impact prescription is unclear, since even before the change as many as half of physicians with a waiver permitting them to prescribe buprenorphine did not do so, and one third of non-waivered physicians reported that nothing would induce them to prescribe buprenorphine for opioid use disorder.[29]

Chronic pain

A transdermal patch is available for the treatment of chronic pain.[8] These patches are not indicated for use in acute pain, pain that is expected to last only for a short period of time, or pain after surgery, nor are they recommended for opioid addiction.[30]


With respect to equianalgesic dosing, when used sublingually, the potency of buprenorphine is about 40 to 70 times that of morphine.[31][32][33] When used as a transdermal patch, the potency of buprenorphine may be 100 to 115 times that of morphine.[31][34]

Veterinary uses

Veterinarians frequently administer buprenorphine for perioperative pain, particularly in cats, where its effects are similar to morphine. The drug's legal status and lower potential for human abuse makes it an attractive alternative to other opioids.[35]

Adverse effects

A 2007 assessment of harm from recreational drug use (mean physical harm and mean dependence liability): Buprenorphine was ranked 9th in dependence, 8th in physical harm, and 11th in social harm.[36]

Common adverse drug reactions associated with the use of buprenorphine, similar to those of other opioids, include nausea and vomiting, drowsiness, dizziness, headache, memory loss, cognitive and neural inhibition, perspiration, itchiness, dry mouth, shrinking of the pupils of the eyes (miosis), orthostatic hypotension, male ejaculatory difficulty, decreased libido, and urinary retention. Constipation and central nervous system (CNS) effects are seen less frequently than with morphine.[37]

Respiratory effects

The most severe side effect associated with buprenorphine is respiratory depression (insufficient breathing).[8] It occurs more often in those who are also taking benzodiazepines or alcohol, or have underlying lung disease.[8] The usual reversal agents for opioids, such as naloxone, may be only partially effective, and additional efforts to support breathing may be required.[8] Respiratory depression may be less than with other opioids, particularly with chronic use.[21] In the setting of acute pain management, though, buprenorphine appears to cause the same rate of respiratory depression as other opioids such as morphine.[38]

Buprenorphine dependence

Buprenorphine treatment carries the risk of causing psychological or physiological (physical) dependencies. It has a slow onset of activity, with a long duration of action, and a long half-life of 24 to 60 hours. Once a patient has stabilised on the (buprenorphine) medication and programme, three options remain - continual use (buprenorphine-only medication), switching to a buprenorphine/naloxone combination, or a medically supervised withdrawal.[21]

Pain management

Achieving acute opioid analgesia is difficult in persons using buprenorphine for pain management.[39]



SiteKi (nM)ActionSpeciesRef
Partial agonistHuman
NOP77.4Partial agonistHuman[42][43][45]
VGSC33,000 (IC50)InhibitorRodent[49]
Values are Ki (nM), unless otherwise noted. The smaller
the value, the more strongly the drug binds to the site.

Opioid receptor modulator

Buprenorphine has been reported to possess these following pharmacological activities:[43]

  • μ-Opioid receptor (MOR): Very high affinity partial agonist:[50] at low doses, the MOR-mediated effects of buprenorphine are comparable to those of other narcotics, but these effects reach a "ceiling" as the receptor population is saturated.[45] This behavior is responsible for several unique properties: buprenorphine greatly reduces the effect of most other MOR agonists,[51] can cause precipitated withdrawal when used in actively opioid dependent persons,[51] and has a lower incidence of respiratory depression and fatal overdose relative to full MOR agonists.[52]
  • κ-Opioid receptor (KOR): High affinity antagonist[50]—this activity is hypothesized to underlie some of the effects of buprenorphine on mood disorders and addiction.[53][54][55]
  • δ-Opioid receptor (DOR): High affinity antagonist[50][56]
  • Nociceptin receptor (NOP, ORL-1): Weak affinity, very weak partial agonist[50]

In simplified terms, buprenorphine can essentially be thought of as a nonselective, mixed agonist–antagonist opioid receptor modulator,[57] acting as an unusually high affinity weak partial agonist of the MOR, a high affinity antagonist of the KOR and DOR, and a relatively low affinity, very weak partial agonist of the ORL-1/NOP.[45][58][51][59][60][61]

Although buprenorphine is a partial agonist of the MOR, human studies have found that it acts like a full agonist with respect to analgesia in opioid-intolerant individuals.[62] Conversely, buprenorphine behaves like a partial agonist of the MOR with respect to respiratory depression.[62]

Buprenorphine is also known to bind to with high affinity and antagonize the putative ε-opioid receptor.[63][64]

Full analgesic efficacy of buprenorphine requires both exon 11-[65] and exon 1-associated μ-opioid receptor splice variants.[66]

The active metabolites of buprenorphine are not thought to be clinically important in its CNS effects.[62]

In positron emission tomography (PET) imaging studies, buprenorphine was found to decrease whole-brain MOR availability due to receptor occupancy by 41% (i.e., 59% availability) at 2 mg, 80% (i.e., 20% availability) at 16 mg, and 84% (i.e., 16% availability) at 32 mg.[67][68][69][70]

Other actions

Unlike some other opioids and opioid antagonists, buprenorphine binds only weakly to and possesses little if any activity at the sigma receptor.[71][72]

Buprenorphine also blocks voltage-gated sodium channels via the local anesthetic binding site, and this underlies its potent local anesthetic properties.[49]

Similarly to various other opioids, buprenorphine has also been found to act as an agonist of the toll-like receptor 4, albeit with very low affinity.[47]


Buprenorphine is metabolized by the liver, via CYP3A4 (also CYP2C8 seems to be involved) isozymes of the cytochrome P450 enzyme system, into norbuprenorphine (by N-dealkylation). The glucuronidation of buprenorphine is primarily carried out by UGT1A1 and UGT2B7, and that of norbuprenorphine by UGT1A1 and UGT1A3. These glucuronides are then eliminated mainly through excretion into bile. The elimination half-life of buprenorphine is 20 to 73 hours (mean 37 hours). Due to the mainly hepatic elimination, no risk of accumulation exists in people with renal impairment.[73]

One of the major active metabolites of buprenorphine is norbuprenorphine, which, in contrast to buprenorphine itself, is a full agonist of the MOR, DOR, and ORL-1, and a partial agonist at the KOR.[74][75] However, relative to buprenorphine, norbuprenorphine has extremely little antinociceptive potency (1/50th that of buprenorphine), but markedly depresses respiration (10-fold more than buprenorphine).[76] This may be explained by very poor brain penetration of norbuprenorphine due to a high affinity of the compound for P-glycoprotein.[76] In contrast to norbuprenorphine, buprenorphine and its glucuronide metabolites are negligibly transported by P-glycoprotein.[76]

The glucuronides of buprenorphine and norbuprenorphine are also biologically active, and represent major active metabolites of buprenorphine.[77] Buprenorphine-3-glucuronide has affinity for the MOR (Ki = 4.9 pM), DOR (Ki = 270 nM) and ORL-1 (Ki = 36 μM), and no affinity for the KOR. It has a small antinociceptive effect and no effect on respiration. Norbuprenorphine-3-glucuronide has no affinity for the MOR or DOR, but does bind to the KOR (Ki = 300 nM) and ORL-1 (Ki = 18 μM). It has a sedative effect but no effect on respiration.


Buprenorphine is a semisynthetic derivative of thebaine,[78] and is fairly soluble in water, as its hydrochloride salt.[79] It degrades in the presence of light.[79]

Detection in body fluids

Buprenorphine and norbuprenorphine may be quantified in blood or urine to monitor use or non-medical recreational use, confirm a diagnosis of poisoning, or assist in a medicolegal investigation. A significant overlap of drug concentrations exists in body fluids within the possible spectrum of physiological reactions ranging from asymptomatic to comatose. Therefore, having knowledge of both the route of administration of the drug and the level of tolerance to opioids of the individual is critical when results are interpreted.[80]


In 1969, researchers at Reckitt and Colman (now Reckitt Benckiser) had spent 10 years attempting to synthesize an opioid compound "with structures substantially more complex than morphine [that] could retain the desirable actions whilst shedding the undesirable side effects". Physical dependence and withdrawal from buprenorphine itself remain important issues, since buprenorphine is a long-acting opioid.[81] Reckitt found success when researchers synthesized RX6029 which had showed success in reducing dependence in test animals. RX6029 was named buprenorphine and began trials on humans in 1971.[82][83] By 1978, buprenorphine was first launched in the UK as an injection to treat severe pain, with a sublingual formulation released in 1982.

Society and culture

United States

In the United States, buprenorphine and buprenorphine with naloxone were approved for opioid use disorder by the Food and Drug Administration in October 2002.[84] The DEA rescheduled buprenorphine from a schedule V drug to a schedule III drug just before approval.[85] The ACSCN for buprenorphine is 9064, and being a schedule III substance, it does not have an annual manufacturing quota imposed by the DEA.[86] The salt in use is the hydrochloride, which has a free-base conversion ratio of 0.928.

In the years before buprenorphine/naloxone was approved, Reckitt Benckiser had lobbied Congress to help craft the Drug Addiction Treatment Act of 2000, which gave authority to the Secretary of Health and Human Services to grant a waiver to physicians with certain training to prescribe and administer schedule III, IV, or V narcotic drugs for the treatment of addiction or detoxification. Before this law was passed, such treatment was permitted only in clinics designed specifically for drug addiction.[87]

The waiver, which can be granted after the completion of an eight-hour course, was required for outpatient treatment of opioid addiction with buprenorphine from 2000 to 2021. Initially, the number of people each approved physician could treat was limited to 10. This was eventually modified to allow approved physicians to treat up to 100 people with buprenorphine for opioid addiction in an outpatient setting.[88] This limit was increased by the Obama administration, raising the number of patients to which doctors can prescribe to 275.[89] On 14 January 2021, the US Department of Health and Human Services announced that the waiver would no longer be required to prescribe buprenorphine to treat up to 30 people concurrently.[90]

New Jersey authorized paramedics to give buprenorphine to people at the scene after they have recovered from an overdose.[91]


In the European Union, Subutex and Suboxone, buprenorphine's high-dose sublingual tablet preparations, were approved for opioid use disorder treatment in September 2006.[92] In the Netherlands, buprenorphine is a list II drug of the Opium Law, though special rules and guidelines apply to its prescription and dispensation. In France, where buprenorphine prescription by general practitioners and dispensed by pharmacies has been permitted since the mid-1990s as a response to HIV and overdose risk. Deaths caused by heroin overdose were reduced by four-fifths between 1994 and 2002, and incidence of AIDS among people who inject drugs in France fell from 25% in the mid-1990s to 6% in 2010.[93]

Brand names

Buprenorphine is available under the trade names Cizdol, Brixadi (weekly and monthly depot injections approved in the US by FDA for addiction treatment in 2020), Suboxone (with naloxone), Subutex (typically used for opioid use disorder), Zubsolv, Bunavail, Buvidal (weekly and monthly depot injections, approved in the UK, Europe and Australia for addiction treatment in 2018), Sublocade (monthly injection, approved in the US in 2018),[94][95][96] Probuphine, Temgesic (sublingual tablets for moderate to severe pain), Buprenex (solutions for injection often used for acute pain in primary-care settings), Norspan, and Butrans (transdermal preparations used for chronic pain).[79] In Poland buprenorphine is available under the trade names Bunondol (for pain treatment, when morphine is too little; amounts of 0.2mg and 0.4mg) and Bunorfin (for addicts substitution in amount of 2 and 8mg).

Buprenorphine has been introduced in most European countries as a transdermal formulation (marketed as Transtec) for the treatment of chronic pain not responding to nonopioids.

Veterinary medicine

It has veterinary medical use for treatment of pain in dogs and cats.[97][98][99][100]



Some evidence supports the use of buprenorphine for depression.[101] Buprenorphine/samidorphan, a combination product of buprenorphine and samidorphan (a preferential μ-opioid receptor antagonist), appears useful for treatment-resistant depression.[102]

Cocaine dependence

In combination with samidorphan or naltrexone (μ-opioid receptor antagonists), buprenorphine is under investigation for the treatment of cocaine dependence, and recently demonstrated effectiveness for this indication in a large-scale (n = 302) clinical trial (at a high buprenorphine dose of 16 mg, but not a low dose of 4 mg).[103][104]

Neonatal abstinence

Buprenorphine has been used in the treatment of the neonatal abstinence syndrome,[105] a condition in which newborns exposed to opioids during pregnancy demonstrate signs of withdrawal.[106] In the United States, use currently is limited to infants enrolled in a clinical trial conducted under an FDA-approved investigational new drug (IND) application.[107] Preliminary research suggests that buprenorphine is associated with shorter time in hospital for neonates, compared to methadone.[108] An ethanolic formulation used in neonates is stable at room temperature for at least 30 days.[109]

Obsessive–compulsive disorder

In one study, buprenorphine was found to be effective in a subset of individuals with treatment-refractory obsessive–compulsive disorder.[110]


  1. "Buprenorphine Use During Pregnancy". Drugs.com. 14 October 2019. Retrieved 17 May 2020.
  2. Bonewit-West K, Hunt AS, Applegate E (2012). Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. p. 571. ISBN 9781455701506.
  3. Health Canada (6 December 2004). "ARCHIVED - Report Stakeholder Workshop on a National Buprenorphine Program". aem. Retrieved 10 January 2020.
  4. Mendelson J, Upton RA, Everhart ET, Jacob P, Jones RT (January 1997). "Bioavailability of sublingual buprenorphine". Journal of Clinical Pharmacology. 37 (1): 31–7. doi:10.1177/009127009703700106. PMID 9048270. S2CID 31735116.
  5. Eriksen J, Jensen NH, Kamp-Jensen M, Bjarnø H, Friis P, Brewster D (November 1989). "The systemic availability of buprenorphine administered by nasal spray". The Journal of Pharmacy and Pharmacology. 41 (11): 803–5. doi:10.1111/j.2042-7158.1989.tb06374.x. PMID 2576057. S2CID 1286222.
  6. "Buprenorphine / Naloxone Buccal Film (BUNAVAIL) C-III" (PDF). Pharmacy Benefits Management (PBM) Services. September 2014.
  7. BioDelivery BioDelivery Sciences International (June 2014). "BUNAVAIL (buprenorphine and naloxone) buccal film, CIII [prescribing information online]" (PDF). U.S. Food and Drug Administration.
  8. "Buprenorphine Hydrochloride". drugs.com. American Society of Health-System Pharmacists. 26 January 2017. Retrieved 17 March 2017.
  9. "Press Announcements – FDA approves first buprenorphine implant for treatment of opioid dependence". FDA. Retrieved 12 December 2017.
  10. Whelan, P. J., & Remski, K. (2012). Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. Journal of neurosciences in rural practice, 3(01), 45-50.
  11. "Buprenorphine". The Substance Abuse and Mental Health Services Administration. Retrieved 14 October 2020.
  12. "Buprenorphine use while Breastfeeding". Drugs.com.
  13. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 528. ISBN 9783527607495.
  14. World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  15. "Buprenorphine". SAMHSA Center for Substance Abuse Treatment (CSAT). July 2019. Archived from the original on 20 August 2020. Retrieved 9 January 2020.
  16. "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  17. "Buprenorphine - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  18. Levounis P, Avery J (2018). "Patient Assessment". In Renner Jr JA, Levounis P, LaRose AT (eds.). Office-based buprenorphine treatment of opioid use disorder. Arlington, VA: American Psychiatric Association Publishing. ISBN 978-1-61537-170-9. OCLC 1002302926.
  19. Restrepo R, Levounis P (2018). "Clinical Use of Buprenorphine". In Renner Jr JA, Levounis P, LaRose AT (eds.). Office-based buprenorphine treatment of opioid use disorder. Arlington, VA: American Psychiatric Association Publishing. ISBN 978-1-61537-170-9. OCLC 1002302926.
  20. "Naloxone Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 2 January 2015. Retrieved 2 January 2015.
  21. "Buprenorphine". www.samhsa.gov. 31 May 2016. Retrieved 3 December 2017.
  22. Sue KL, Cohen S, Tilley J, Yocheved A (January 2022). "A Plea From People Who Use Drugs to Clinicians: New Ways to Initiate Buprenorphine are Urgently Needed in the Fentanyl Era". Journal of Addiction Medicine. 16 (4): 389–391. doi:10.1097/ADM.0000000000000952. PMID 35020693. S2CID 245925947.
  23. Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, et al. (20 July 2016). "Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method". Substance Abuse and Rehabilitation. 7: 99–105. doi:10.2147/SAR.S109919. PMC 4959756. PMID 27499655.
  24. Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J (July 2021). "Microinduction of Buprenorphine/Naloxone: A Review of the Literature". The American Journal on Addictions. 30 (4): 305–315. doi:10.1111/ajad.13135. PMID 33378137. S2CID 229721826.
  25. Gowing L, Ali R, White JM, Mbewe D (February 2017). "Buprenorphine for managing opioid withdrawal". The Cochrane Database of Systematic Reviews. 2017 (2): CD002025. doi:10.1002/14651858.CD002025.pub5. PMC 6464315. PMID 28220474.
  26. Lemon LS, Caritis SN, Venkataramanan R, Platt RW, Bodnar LM (March 2018). "Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome". Epidemiology. 29 (2): 261–268. doi:10.1097/EDE.0000000000000780. PMC 5792296. PMID 29112519. Methadone is associated with increased risk of neonatal abstinence syndrome compared with buprenorphine in infants exposed in utero. This association is subject to minimal bias due to unmeasured confounding by severity of addiction.
  27. Auriacombe M, Fatséas M, Dubernet J, Daulouède JP, Tignol J (2004). "French field experience with buprenorphine". The American Journal on Addictions. 13 (Suppl 1): S17–S28. doi:10.1080/10550490490440780. PMID 15204673.
  28. Health (OASH), Office of the Assistant Secretary for (14 January 2021). "HHS Expands Access to Treatment for Opioid Use Disorder". HHS.gov. Retrieved 5 January 2022.
  29. Stringfellow EJ, Humphreys K, Jalali MS. "Removing The X-Waiver Is One Small Step Toward Increasing Treatment Of Opioid Use Disorder, But Great Leaps Are Needed". Health Affairs Forefront. Retrieved 5 January 2022.
  30. "Butrans Medication Guide". Butrans Medication Guide. Purdue Pharma L.P. Retrieved 7 July 2014.
  31. Cote J, Montgomery L (July 2014). "Sublingual buprenorphine as an analgesic in chronic pain: a systematic review". Pain Medicine. 15 (7): 1171–8. doi:10.1111/pme.12386. PMID 24995716.
  32. "Drug Enforcement Administration (2005). "Ch. 4 Narcotics: Narcotics Treatment Drugs: Buprenorphine". Drugs of Abuse. U.S. Department of Justice. Archived from the original on 2 November 2006.
  33. "Opioid Conversion Guide" (PDF). Department of Health, Government of Western Australia. February 2016.
  34. Khanna IK, Pillarisetti S (2015). "Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain". Journal of Pain Research. 8: 859–70. doi:10.2147/JPR.S85951. PMC 4675640. PMID 26672499.
  35. Martinez M. "Options in perioperative analgesia: buprenorphine v. methadone". Veterinary Practice. Retrieved 19 January 2022.
  36. Nutt D, King LA, Saulsbury W, Blakemore C (March 2007). "Development of a rational scale to assess the harm of drugs of potential misuse". Lancet. 369 (9566): 1047–53. doi:10.1016/S0140-6736(07)60464-4. PMID 17382831. S2CID 5903121.
  37. Budd K, Raffa RB. (eds.) Buprenorphine – The unique opioid analgesic. Thieme, 200, ISBN 3-13-134211-0
  38. White LD, Hodge A, Vlok R, Hurtado G, Eastern K, Melhuish TM (April 2018). "Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials". British Journal of Anaesthesia. 120 (4): 668–678. doi:10.1016/j.bja.2017.11.086. PMID 29576108.
  39. Alford DP, Compton P, Samet JH (January 2006). "Acute pain management for patients receiving maintenance methadone or buprenorphine therapy". Annals of Internal Medicine. 144 (2): 127–34. doi:10.7326/0003-4819-144-2-200601170-00010. PMC 1892816. PMID 16418412.
  40. Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
  41. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, et al. (March 1998). "Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications". NIDA Research Monograph. 178: 440–66. PMID 9686407.
  42. Khroyan TV, Polgar WE, Jiang F, Zaveri NT, Toll L (December 2009). "Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists". The Journal of Pharmacology and Experimental Therapeutics. 331 (3): 946–53. doi:10.1124/jpet.109.156711. PMC 2784721. PMID 19713488.
  43. Khroyan TV, Wu J, Polgar WE, Cami-Kobeci G, Fotaki N, Husbands SM, Toll L (January 2015). "BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice". British Journal of Pharmacology. 172 (2): 668–80. doi:10.1111/bph.12796. PMC 4292977. PMID 24903063.
  44. Negus SS, Bidlack JM, Mello NK, Furness MS, Rice KC, Brandt MR (November 2002). "Delta opioid antagonist effects of buprenorphine in rhesus monkeys". Behavioural Pharmacology. 13 (7): 557–70. doi:10.1097/00008877-200211000-00005. PMID 12409994.
  45. Lutfy K, Cowan A (October 2004). "Buprenorphine: a unique drug with complex pharmacology". Current Neuropharmacology. 2 (4): 395–402. doi:10.2174/1570159043359477. PMC 2581407. PMID 18997874.
  46. Freye E (1987). "Interaction of Mixed Agonist-Antagonists with Different Receptor Sites Using Nalbuphine as a Model Substance". Opioid Agonists, Antagonists and Mixed Narcotic Analgesics. pp. 67–78. doi:10.1007/978-3-642-71854-0_6. ISBN 978-3-540-17471-4.
  47. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, et al. (January 2010). "Evidence that opioids may have toll-like receptor 4 and MD-2 effects". Brain, Behavior, and Immunity. 24 (1): 83–95. doi:10.1016/j.bbi.2009.08.004. PMC 2788078. PMID 19679181.
  48. Codd EE, Shank RP, Schupsky JJ, Raffa RB (September 1995). "Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception". The Journal of Pharmacology and Experimental Therapeutics. 274 (3): 1263–70. PMID 7562497.
  49. Leffler A, Frank G, Kistner K, Niedermirtl F, Koppert W, Reeh PW, Nau C (June 2012). "Local anesthetic-like inhibition of voltage-gated Na(+) channels by the partial μ-opioid receptor agonist buprenorphine". Anesthesiology. 116 (6): 1335–46. doi:10.1097/ALN.0b013e3182557917. PMID 22504149.
  50. Gudin J, Fudin J (June 2020). "A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain". Pain and Therapy. 9 (1): 41–54. doi:10.1007/s40122-019-00143-6. PMC 7203271. PMID 31994020.
  51. Robinson SE (2002). "Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction". CNS Drug Reviews. 8 (4): 377–90. doi:10.1111/j.1527-3458.2002.tb00235.x. PMC 6741692. PMID 12481193.
  52. Khanna IK, Pillarisetti S (2015). "Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain". Journal of Pain Research. 8: 859–870. doi:10.2147/JPR.S85951. PMC 4675640. PMID 26672499.
  53. Madison CA, Eitan S (April 2020). "Buprenorphine: prospective novel therapy for depression and PTSD". Psychological Medicine. 50 (6): 881–893. doi:10.1017/S0033291720000525. PMID 32204739. S2CID 214630021.
  54. Stefanowski B, Antosik-Wójcińska A, Święcicki Ł (April 2020). "The use of buprenorphine in the treatment of drug-resistant depression - an overview of the studies". Psychiatria Polska. 54 (2): 199–207. doi:10.12740/PP/102658. PMID 32772054.
  55. Carlezon WA, Béguin C, Knoll AT, Cohen BM (September 2009). "Kappa-opioid ligands in the study and treatment of mood disorders". Pharmacology & Therapeutics. 123 (3): 334–343. doi:10.1016/j.pharmthera.2009.05.008. PMC 2740476. PMID 19497337.
  56. Benzon H, Raja S, Fishman S, Liu SS, Cohen SP (2017). Essentials of Pain Medicine E-Book. Elsevier Health Sciences. p. 382. ISBN 9780323445412.
  57. Jacob JJ, Michaud GM, Tremblay EC (1979). "Mixed agonist-antagonist opiates and physical dependence". British Journal of Clinical Pharmacology. 7 (Suppl 3): 291S–296S. doi:10.1111/j.1365-2125.1979.tb04703.x. PMC 1429306. PMID 572694.
  58. Kress HG (March 2009). "Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine". European Journal of Pain. 13 (3): 219–30. doi:10.1016/j.ejpain.2008.04.011. PMID 18567516. S2CID 8243410.
  59. Ruiz P, Strain EC (2011). Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook. Lippincott Williams & Wilkins. p. 439. ISBN 978-1-60547-277-5.
  60. Bidlack JM (2014). "Mixed kappa/mu partial opioid agonists as potential treatments for cocaine dependence". Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Adv. Pharmacol. Advances in Pharmacology. Vol. 69. pp. 387–418. doi:10.1016/B978-0-12-420118-7.00010-X. ISBN 9780124201187. PMID 24484983.
  61. Ehrich E, Turncliff R, Du Y, Leigh-Pemberton R, Fernandez E, Jones R, Fava M (May 2015). "Evaluation of opioid modulation in major depressive disorder". Neuropsychopharmacology. 40 (6): 1448–55. doi:10.1038/npp.2014.330. PMC 4397403. PMID 25518754.
  62. Coller JK, Christrup LL, Somogyi AA (February 2009). "Role of active metabolites in the use of opioids". European Journal of Clinical Pharmacology. 65 (2): 121–39. doi:10.1007/s00228-008-0570-y. PMID 18958460. S2CID 9977741.
  63. Mizoguchi H, Wu HE, Narita M, Hall FS, Sora I, Uhl GR, et al. (2002). "Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse". Neuroscience. 115 (3): 715–21. doi:10.1016/s0306-4522(02)00486-4. PMID 12435410. S2CID 54316989.
  64. Mizoguchi H, Spaulding A, Leitermann R, Wu HE, Nagase H, Tseng LF (July 2003). "Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse". The Journal of Pharmacology and Experimental Therapeutics. 306 (1): 394–400. doi:10.1124/jpet.103.048835. PMID 12721333. S2CID 44036890.
  65. Xu J, Xu M, Hurd YL, Pasternak GW, Pan YX (February 2009). "Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene". Journal of Neurochemistry. 108 (4): 962–72. doi:10.1111/j.1471-4159.2008.05833.x. PMC 2727151. PMID 19077058.
  66. Grinnell S et al. (2014): Buprenorphine analgesia requires exon 11-associated mu opioid receptor splice variants. The FASEB Journal
  67. Colasanti A, Lingford-Hughes A, Nutt D (2013). "Opioids Neuroimaging". In Miller PM (ed.). Biological Research on Addiction. Comprehensive Addictive Behaviors and Disorders. Vol. 2. Elsevier. pp. 675–687. doi:10.1016/B978-0-12-398335-0.00066-2. ISBN 9780123983350.
  68. Zubieta J, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM, Koeppe RA, Schuster CR, Johanson CE (September 2000). "Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study". Neuropsychopharmacology. 23 (3): 326–34. doi:10.1016/S0893-133X(00)00110-X. PMID 10942856. S2CID 27350905.
  69. Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, Zubieta JK (November 2003). "Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers". Neuropsychopharmacology. 28 (11): 2000–9. doi:10.1038/sj.npp.1300251. PMID 12902992. S2CID 20773085.
  70. Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, Koeppe R, Zubieta JK (January 2007). "Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices". Biol Psychiatry. 61 (1): 101–10. doi:10.1016/j.biopsych.2006.04.043. PMID 16950210. S2CID 46105421.
  71. Doweiko HE (14 March 2014). Concepts of Chemical Dependency. Cengage Learning. pp. 149–. ISBN 978-1-285-45717-8.
  72. USP DI. United States Pharmacopeial Convention. 1997. ISBN 9780913595947.
  73. Moody DE, Fang WB, Lin SN, Weyant DM, Strom SC, Omiecinski CJ (December 2009). "Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes". Drug Metabolism and Disposition. 37 (12): 2323–9. doi:10.1124/dmd.109.028605. PMC 2784702. PMID 19773542.
  74. Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M (May 2007). "Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats". The Journal of Pharmacology and Experimental Therapeutics. 321 (2): 598–607. doi:10.1124/jpet.106.115972. PMID 17283225. S2CID 11921738.
  75. Huang P, Kehner GB, Cowan A, Liu-Chen LY (May 2001). "Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist". The Journal of Pharmacology and Experimental Therapeutics. 297 (2): 688–95. PMID 11303059.
  76. Brown SM, Campbell SD, Crafford A, Regina KJ, Holtzman MJ, Kharasch ED (October 2012). "P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception". The Journal of Pharmacology and Experimental Therapeutics. 343 (1): 53–61. doi:10.1124/jpet.112.193433. PMC 3464040. PMID 22739506.
  77. Brown SM, Holtzman M, Kim T, Kharasch ED (December 2011). "Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active". Anesthesiology. 115 (6): 1251–60. doi:10.1097/ALN.0b013e318238fea0. PMC 3560935. PMID 22037640.
  78. Heel RC, Brogden RN, Speight TM, Avery GS (February 1979). "Buprenorphine: a review of its pharmacological properties and therapeutic efficacy". Drugs. 17 (2): 81–110. doi:10.2165/00003495-197917020-00001. PMID 378645. S2CID 19577410.
  79. "Buprenorphine". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. 14 January 2014. Retrieved 6 April 2014.
  80. Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 190–192. ISBN 978-0962652370.
  81. "IMPORTANT SAFETY INFORMATION". Archived from the original on 18 March 2019. Retrieved 25 June 2016.
  82. Campbell ND, Lovell AM (February 2012). "The history of the development of buprenorphine as an addiction therapeutic". Annals of the New York Academy of Sciences. 1248 (1): 124–39. Bibcode:2012NYASA1248..124C. doi:10.1111/j.1749-6632.2011.06352.x. PMID 22256949. S2CID 28395410.
  83. Louis S. Harris, ed. (1998). Problems of Drug Dependence, 1998: Proceedings of the 66th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc (PDF). NIDA Research Monograph 179. Archived from the original (PDF) on 3 December 2016. Retrieved 5 August 2012.
  84. McCormick CG (8 October 2002). "Subutex and Suboxone Approval Letter]" (PDF). Letter to Reckitt Benckiser. U.S. Food and Drug Administration.
  85. 67 FR 62354, 7 October 2002
  86. "Quotas – Conversion Factors for Controlled Substances". Deadiversion.usdoj.gov. Archived from the original on 2 March 2016. Retrieved 7 November 2016.
  87. "Drug Addiction Treatment Act of 2000". SAMHSA, U.S. Department of Health & Human Services. Archived from the original on 4 March 2013.
  88. "The National Alliance of Advocates for Buprenorphine Treatment". naabt.org. Retrieved 19 May 2013.
  89. "Obama administration's change on buprenorphine policy". Business Insider. 6 July 2016. Retrieved 7 November 2016.
  90. "HHS Expands Access to Treatment for Opioid Use Disorder". US Deptartment of Health and Human Services. 14 January 2021. Retrieved 14 January 2021.
  91. "In national first, N.J. program will let paramedics administer buprenorphine". STAT. 26 June 2019. Retrieved 21 November 2019.
  92. "Suboxone EU Approval". Ema.europa.eu. Retrieved 7 November 2016.
  93. Poloméni P, Schwan R (3 March 2014). "Management of opioid addiction with buprenorphine: French history and current management". International Journal of General Medicine. 7: 143–148. doi:10.2147/IJGM.S53170. PMC 3949694. PMID 24623988.
  94. "Press Announcements – FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder". www.fda.gov. Retrieved 5 December 2017.
  95. "Indivior drug to fight opioid addiction approved by U.S. FDA". Reuters. 2017. Retrieved 5 December 2017.
  96. "Sublocade Now Available for Moderate-to-Severe Opioid Use Disorder". MPR. 1 March 2018. Retrieved 23 September 2019.
  97. Claude A (June 2015). "Buprenorphine" (PDF). cliniciansbrief.com. Archived from the original (PDF) on 16 May 2017. Retrieved 25 February 2017.
  98. Kukanich B, Papich MG (14 May 2013). "Opioid Analgesic Drugs". In Riviere JE, Papich MG (eds.). Veterinary Pharmacology and Therapeutics (9th ed.). John Wiley & Sons. pp. 323–325. ISBN 9781118685907.
  99. Steagall PV, Ruel HL, Yasuda T, Monteiro BP, Watanabe R, Evangelista MC, Beaudry F (May 2020). "Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial". BMC Veterinary Research. 16 (1): 154. doi:10.1186/s12917-020-02364-w. PMC 7245774. PMID 32448336.
  100. "Buprenorphine (Buprenex) For Cats and Dogs: What Are The Side Effects and Alternatives?". Relievet. Retrieved 10 December 2020.
  101. Stanciu CN, Glass OM, Penders TM (April 2017). "Use of Buprenorphine in treatment of refractory depression-A review of current literature". Asian Journal of Psychiatry. 26: 94–98. doi:10.1016/j.ajp.2017.01.015. PMID 28483102.
  102. Ragguett RM, Rong C, Rosenblat JD, Ho RC, McIntyre RS (April 2018). "Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder". Expert Opinion on Drug Metabolism & Toxicology. 14 (4): 475–482. doi:10.1080/17425255.2018.1459564. PMID 29621905. S2CID 4633923.
  103. Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, et al. (August 2016). "Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study". Addiction. 111 (8): 1416–27. doi:10.1111/add.13375. PMC 4940267. PMID 26948856.
  104. "Alkermes Presents Positive Clinical Data of ALKS 5461 at 52nd Annual New Clinical Drug Evaluation Unit Meeting". Reuters. 2012. Archived from the original on 24 September 2015. Retrieved 30 June 2017.
  105. Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, et al. (September 2008). "Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial". Pediatrics. 122 (3): e601-7. doi:10.1542/peds.2008-0571. PMC 2574639. PMID 18694901.
  106. Kraft WK, van den Anker JN (October 2012). "Pharmacologic management of the opioid neonatal abstinence syndrome". Pediatric Clinics of North America. 59 (5): 1147–65. doi:10.1016/j.pcl.2012.07.006. PMC 4709246. PMID 23036249.
  107. Clinical trial number NCT00521248 for "Buprenorphine for the Treatment of Neonatal Abstinence Syndrome" at ClinicalTrials.gov
  108. Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ (July 2017). "Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women". Pharmacotherapy. 37 (7): 824–839. doi:10.1002/phar.1958. PMID 28543191. S2CID 13772333. Currently, methadone and buprenorphine are both widely used as the backbone of MAT [medication-assisted treatment]. The distinguishing outcomes in studies among these two opioid agonists are that infants exposed to buprenorphine in clinical trials required shorter treatment duration, less medication to treat the NAS symptoms and experienced shorter hospitalizations compared to infants exposed to methadone. A caveat to these findings is that some of the supporting data were based on using buprenorphine in combination with naloxone instead of buprenorphine as a single agent.
  109. Anagnostis EA, Sadaka RE, Sailor LA, Moody DE, Dysart KC, Kraft WK (October 2011). "Formulation of buprenorphine for sublingual use in neonates". The Journal of Pediatric Pharmacology and Therapeutics. 16 (4): 281–4. doi:10.5863/1551-6776-16.4.281. PMC 3385042. PMID 22768012.
  110. Liddell MB, Aziz V, Briggs P, Kanakkehewa N, Rawi O (February 2013). "Buprenorphine augmentation in the treatment of refractory obsessive-compulsive disorder". Therapeutic Advances in Psychopharmacology. 3 (1): 15–9. doi:10.1177/2045125312462233. PMC 3736962. PMID 23983988.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.